Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | P2RX3 | P56373 | 5/20 | 0.33 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.30 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20046729 | 0.88 | MEN1 (0.43) | L3MBTL1MEN1KMT2AKDM4CNPC1 | |
| SCHEMBL20046723 | 0.80 | KDM4C (0.45) | L3MBTL1MEN1KMT2AKDM4CNPC1 | |
| SCHEMBL10742413 | 0.77 | MEN1 (0.50) | L3MBTL1MEN1KMT2AKDM4CNPC1 | |
| SCHEMBL79915 | 0.76 | L3MBTL1 (0.44) | L3MBTL1MEN1KMT2AKDM4CNPC1 | |
| SCHEMBL17607014 | 0.75 | MEN1 (0.50) | L3MBTL1MEN1KMT2AKDM4CNPC1 | |
| SCHEMBL17624780 | 0.74 | MEN1 (0.55) | L3MBTL1MEN1KMT2AKDM4CNPC1 | |
| SCHEMBL17606882 | 0.74 | MEN1 (0.52) | L3MBTL1MEN1KMT2AKDM4CNPC1 | |
| SCHEMBL22922185 | 0.73 | MEN1 (0.54) | L3MBTL1MEN1KMT2AKDM4CNPC1 | |
| SCHEMBL79454 | 0.73 | SLC6A2 (0.44) | L3MBTL1MEN1KMT2AKDM4CNPC1 | |
| SCHEMBL23691407 | 0.72 | MEN1 (0.45) | L3MBTL1MEN1KMT2AKDM4CNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | ARVINAS OPERATIONS, INC. | 2023-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331681-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF ANDROGEN RECEPTOR | AR, ADRM1, CRBN | L3MBTL1 2898/4885MEN1 1674/4885KMT2A 1463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.